A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

NCT04495933 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

216

Enrollment

OTHER

Sponsor class

Conditions

SARS-CoV2
Covid19

Interventions

BIOLOGICAL: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg
BIOLOGICAL: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg
BIOLOGICAL: MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg
OTHER: Placebo

Sponsor

The University of Queensland

Collaborators

[object Object]
[object Object]